| 16.35 Delayed Data As of Sep 16 |  +0.07 / +0.43%Today’s Change | 13.24 Today|||52-Week Range 18.76 | +11.76% Year-to-Date |
| Roche's New Perjeta Combo Meets Goal in Breast Cancer Study Sep 13 / Zacks.com - Paid Partner Content |
| Previous close | 16.28 |
| Today’s open | 16.15 |
| Day’s range | 16.09 - 16.46 |
| Volume | 605,241 |
| Average volume (3 months) | 839,340 |
| Market cap | $2.4B |
| Earnings growth (last year) | -221.61% |
| Earnings growth (this year) | +36.35% |
| Earnings growth (next 5 years) | +55.00% |
| Revenue growth (last year) | -52.04% |
| P/E ratio | NM |
| Price/Sales | 13.83 |
| Price/Book | 9.46 |
| Today’s change | Today’s % change | |
|---|---|---|
| IMMUImmunomedics Inc | +0.60 | +3.59% |
| XLRNAcceleron Pharma Inc | +0.75 | +1.71% |
| TLRYTilray Inc | -0.86 | -2.72% |
| CRSPCRISPR Therapeutics ... | +2.00 | +4.20% |
| Next reporting date | November 5, 2019 |
| EPS forecast (this quarter) | -$0.12 |
| Annual revenue (last year) | $151.9M |
| Annual profit (last year) | -$80.3M |
| Net profit margin | -52.90% |
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters --, -- |
